Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMIE W FERNANDEZ

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1326176736
CMS profile
1055985
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$118,431.82

122 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $112,807.75 115
Janssen Scientific Affairs, LLC $2,525.00 1
Janssen Global Services, LLC $2,020.00 1
Sage Therapeutics, Inc. $800.00 1
LivaNova USA, Inc. $121.44 1
ITI, Inc. $115.91 1
AbbVie Inc. $23.71 1
Otsuka America Pharmaceutical, Inc. $18.01 1

Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMIE W FERNANDEZ

NPI 1326176736 · CMS profile ID 1055985

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326176736?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMIE W FERNANDEZ, NPI 1326176736, CMS profile ID 1055985. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326176736?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JAMIE W FERNANDEZ, NPI 1326176736, CMS profile ID 1055985. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326176736?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JAMIE W FERNANDEZ, NPI 1326176736, CMS profile ID 1055985, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1326176736?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

122 matching records · $118,431.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 122 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 122.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $366.1410/06/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116825 CMS
Janssen Pharmaceuticals, Inc $16.3110/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116847 CMS
Janssen Pharmaceuticals, Inc $22.4010/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116855 CMS
Janssen Pharmaceuticals, Inc $121.0910/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116875 CMS
Janssen Pharmaceuticals, Inc $1,060.7310/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116803 CMS
Janssen Pharmaceuticals, Inc $366.1410/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116805 CMS
Janssen Pharmaceuticals, Inc $100.6810/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116849 CMS
Janssen Pharmaceuticals, Inc $13.7710/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116851 CMS
Janssen Pharmaceuticals, Inc $3,535.0010/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116733 CMS
Janssen Pharmaceuticals, Inc $1,767.5010/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116739 CMS
Janssen Pharmaceuticals, Inc $3,535.0010/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116741 CMS
Janssen Pharmaceuticals, Inc $121.5009/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116871 CMS
Janssen Pharmaceuticals, Inc $150.7009/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116747 CMS
Janssen Pharmaceuticals, Inc $629.5209/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116749 CMS
Janssen Pharmaceuticals, Inc $9.5809/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116873 CMS
Janssen Pharmaceuticals, Inc $464.9109/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116737 CMS
Janssen Pharmaceuticals, Inc $92.5909/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116883 CMS
Janssen Pharmaceuticals, Inc $1,010.0009/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116721 CMS
Janssen Pharmaceuticals, Inc $1,010.0009/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116723 CMS
Janssen Pharmaceuticals, Inc $3,030.0009/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116725 CMS
Janssen Pharmaceuticals, Inc $1,022.3309/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116731 CMS
Janssen Pharmaceuticals, Inc $13.1509/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116885 CMS
Janssen Pharmaceuticals, Inc $63.0009/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116887 CMS
AbbVie Inc. $23.7109/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794458811 CMS
Janssen Pharmaceuticals, Inc $1,010.0009/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116719 CMS
LivaNova USA, Inc. $121.4409/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844262609 CMS
Janssen Pharmaceuticals, Inc $3,535.0009/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116717 CMS
Janssen Pharmaceuticals, Inc $123.3609/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116893 CMS
Janssen Pharmaceuticals, Inc $1,010.0008/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116699 CMS
Janssen Pharmaceuticals, Inc $3,030.0008/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116705 CMS
Janssen Pharmaceuticals, Inc $3,535.0008/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116713 CMS
Janssen Pharmaceuticals, Inc $16.9008/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116765 CMS
Janssen Pharmaceuticals, Inc $450.8008/30/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116767 CMS
Janssen Pharmaceuticals, Inc $1,010.0008/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116773 CMS
Janssen Pharmaceuticals, Inc $563.6708/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116715 CMS
Janssen Pharmaceuticals, Inc $120.0008/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116843 CMS
Janssen Pharmaceuticals, Inc $124.5808/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116857 CMS
Janssen Pharmaceuticals, Inc $665.4408/19/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116711 CMS
Janssen Pharmaceuticals, Inc $125.0008/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116869 CMS
Janssen Pharmaceuticals, Inc $431.9908/18/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116703 CMS
Janssen Pharmaceuticals, Inc $1,010.0008/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116769 CMS
Janssen Pharmaceuticals, Inc $1,010.0008/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116771 CMS
ITI, Inc. $115.9108/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830132367 CMS
Janssen Pharmaceuticals, Inc $20.3608/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116853 CMS
Janssen Pharmaceuticals, Inc $1,010.0008/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116729 CMS
Janssen Pharmaceuticals, Inc $3,535.0008/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116763 CMS
Janssen Pharmaceuticals, Inc $92.3607/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116899 CMS
Janssen Pharmaceuticals, Inc $1,010.0007/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116697 CMS
Janssen Pharmaceuticals, Inc $1,010.0007/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116701 CMS
Janssen Pharmaceuticals, Inc $3,535.0007/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788116707 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $47,397.17 67
PY2020 $35,186.13 46
PY2021 $118,431.82 122
PY2022 $133,642.02 197
PY2023 $69,137.31 91
PY2024 $11,528.96 29
PY2025 $2,418.05 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $101,129.06 3
PY2025 Principal investigator $1,232,933.77 139
PY2024 Recipient $228,441.72 15
PY2024 Principal investigator $837,638.43 116
PY2023 Recipient $22,064.00 1
PY2023 Principal investigator $376,799.36 27
PY2022 Recipient $7,992.05 1
PY2022 Principal investigator $2,670.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

142 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $8,291.00 12/18/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425759
Principal investigator 1 Janssen Research & Development, LLC $4,185.00 12/05/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175425792
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 12/04/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242368379
Principal investigator 1 Janssen Research & Development, LLC $612.00 12/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425735
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700400
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700402
Principal investigator 1 Boehringer Ingelheim International GmbH $1,544.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700404
Principal investigator 1 Boehringer Ingelheim International GmbH $1,544.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700406
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700408
Principal investigator 1 Boehringer Ingelheim International GmbH $1,484.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700410
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700412
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700414
Principal investigator 1 Boehringer Ingelheim International GmbH $1,544.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700416
Principal investigator 1 Boehringer Ingelheim International GmbH $1,484.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700418
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700420
Principal investigator 1 Boehringer Ingelheim International GmbH $1,544.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700422
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700424
Principal investigator 1 Boehringer Ingelheim International GmbH $1,544.00 11/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700426
Principal investigator 1 Janssen Research & Development, LLC $3,622.00 11/14/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425729
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 11/05/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242365507
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 11/05/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242365509
Principal investigator 1 Janssen Research & Development, LLC $3,106.00 10/30/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175425743
Principal investigator 1 Janssen Research & Development, LLC $2,544.00 10/27/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425783
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700368
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700370
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700372
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700374
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700376
Principal investigator 1 Boehringer Ingelheim International GmbH $1,484.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700378
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700380
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700382
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700384
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700386
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700388
Principal investigator 1 Boehringer Ingelheim International GmbH $1,484.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700390
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700392
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700394
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700396
Principal investigator 1 Boehringer Ingelheim International GmbH $1,484.00 10/02/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700398
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $160.50 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362483
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362485
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $75.00 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362487
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362489
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,700.00 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362491
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $75.00 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362493
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $141.00 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362495
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $170.00 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362497
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $368.60 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362499
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362905
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 10/02/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ
ITI-007-452 No dispute reported 06/30/2026 1242362907
Principal investigator 1 Janssen Research & Development, LLC $2,613.00 09/29/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175425826
Principal investigator 1 Janssen Research & Development, LLC $5,832.00 09/29/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425841
Principal investigator 1 Janssen Research & Development, LLC $16,696.00 09/15/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425689
Principal investigator 1 Janssen Research & Development, LLC $824.00 09/08/2025 Non-covered Recipient Entity
Jamie Winderbaum Fernandez MD Pa
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175201796
Principal investigator 1 Janssen Research & Development, LLC $7,290.00 09/01/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175425753
Principal investigator 1 Janssen Research & Development, LLC $12,086.00 08/29/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425763
Principal investigator 1 Janssen Research & Development, LLC $3,852.00 08/29/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425821
Principal investigator 1 Boehringer Ingelheim International GmbH $2,289.00 08/22/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700358
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700360
Principal investigator 1 Boehringer Ingelheim International GmbH $1,484.00 08/22/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700362
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700364
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700366
Principal investigator 1 Janssen Research & Development, LLC $144.00 08/20/2025 Non-covered Recipient Entity
Jamie Winderbaum Fernandez MD Pa
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175201845
Principal investigator 1 Janssen Research & Development, LLC $448.00 08/11/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425694
Principal investigator 1 Boehringer Ingelheim International GmbH $10,000.00 08/04/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700356
Principal investigator 1 Boehringer Ingelheim International GmbH $2,289.00 07/28/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700340
Principal investigator 1 Boehringer Ingelheim International GmbH $2,289.00 07/28/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700342
Principal investigator 1 Boehringer Ingelheim International GmbH $2,289.00 07/28/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700344
Principal investigator 1 Boehringer Ingelheim International GmbH $2,289.00 07/28/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700346
Principal investigator 1 Boehringer Ingelheim International GmbH $2,289.00 07/28/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700348
Principal investigator 1 Boehringer Ingelheim International GmbH $2,289.00 07/28/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700350
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/28/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700352
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/28/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700354
Principal investigator 1 Janssen Research & Development, LLC $10,308.00 07/28/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425706
Principal investigator 1 Janssen Research & Development, LLC $18,000.00 07/28/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425831
Principal investigator 1 Janssen Research & Development, LLC $2,931.00 07/22/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425713
Principal investigator 1 Janssen Research & Development, LLC $3,758.00 07/10/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175425717
Principal investigator 1 Janssen Research & Development, LLC $9,900.00 07/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425700
Principal investigator 1 Janssen Research & Development, LLC $24,350.00 07/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425748
Principal investigator 1 Janssen Research & Development, LLC $3,852.00 07/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425835
Principal investigator 1 Janssen Research & Development, LLC $9,086.00 06/30/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175425767
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,427.11 06/25/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease No dispute reported 06/30/2026 1235996531
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $385.35 06/24/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235996529
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,898.00 06/23/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242351518
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,020.00 06/23/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242351520
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,155.00 06/23/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242351522
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,644.00 06/23/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242351524
Principal investigator 1 Janssen Research & Development, LLC $34,642.00 05/29/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425773
Principal investigator 1 Boehringer Ingelheim International GmbH $264.55 05/22/2025 Non-covered Recipient Entity
Interventional Psychiatry Of Tampa Bay-Dale Mabry Highway
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220700428
Principal investigator 1 Janssen Research & Development, LLC $49,804.00 05/22/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175425777
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,331.00 05/09/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242347388
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,020.00 05/09/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242347390
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,898.00 05/09/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242347392
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,426.00 05/09/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242347394
Principal investigator 1 Janssen Research & Development, LLC $1,424.00 05/07/2025 Non-covered Recipient Entity
Jamie Winderbaum Fernandez MD Pa
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175201387
Principal investigator 1 Janssen Research & Development, LLC $14,983.00 05/05/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425724
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,360.00 04/14/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242343587
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,360.00 04/14/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242343589
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,644.00 04/14/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242343591
Principal investigator 1 Janssen Research & Development, LLC $1,424.00 04/09/2025 Non-covered Recipient Entity
Jamie Winderbaum Fernandez MD Pa
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175202860
Principal investigator 1 Janssen Research & Development, LLC $5,569.00 04/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425809
Principal investigator 1 Janssen Research & Development, LLC $50,876.00 04/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425815
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 03/19/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242338457
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,360.00 03/17/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242338065
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,360.00 03/17/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242338067
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,331.00 03/17/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242338069
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,155.00 03/17/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242338071
Principal investigator 1 Janssen Research & Development, LLC $2,007.00 03/12/2025 Non-covered Recipient Entity
Jamie Winderbaum Fernandez MD Pa
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175202753
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $143.00 03/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242334756
Recipient E.R. Squibb & Sons, L.L.C. $17,138.68 02/12/2025 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1236002279
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332170
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,157.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332172
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,157.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332174
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332176
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332178
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332282
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332370
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332372
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332374
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,497.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332376
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,739.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332378
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332380
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332382
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332466
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,024.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332468
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332470
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332472
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332600
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332602
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,686.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332604
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,129.00 02/07/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-452 No dispute reported 06/30/2026 1242332606
Recipient E.R. Squibb & Sons, L.L.C. $28,088.88 02/05/2025 Covered Recipient Physician Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1236002277
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $74.18 02/05/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242329999
Recipient E.R. Squibb & Sons, L.L.C. $55,901.50 01/24/2025 Covered Recipient Physician A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1236002275
Principal investigator 1 Janssen Research & Development, LLC $23,105.00 01/24/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425804
Principal investigator 1 Janssen Research & Development, LLC $13,527.00 01/23/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175425800
Principal investigator 1 Janssen Research & Development, LLC $1,224.00 01/15/2025 Non-covered Recipient Entity
Jamie Winderbaum Fernandez MD Pa
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175202915
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $68.12 01/08/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242328364
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $68.12 01/08/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242328366
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $309.18 01/08/2025 Non-covered Recipient Entity
JAMIE WINDERBAUM FERNANDEZ MD PA
ITI-007-505 No dispute reported 06/30/2026 1242328416
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $245,173.06 01/06/2025 Non-covered Recipient Entity
Jamie Winderbaum Fernandez, Md, Pa
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) No dispute reported 06/30/2026 1235996497
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $407,708.00 01/03/2025 Non-covered Recipient Entity
Jamie Winderbaum Fernandez, Md, Pa
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1235996499